Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Patrick Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target fro...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-e...
B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $20 price target.
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corpo...
Latest findings on Altimmune's pemvidutide on body composition: lean mass preservation, significant weight loss from adipos...
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.43) by...
